FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

BACKGROUND: FOLFOX second-line treatment seems to be a validated option for patients with pancreatic cancer (PC) progressing after gemcitabine chemotherapy. However, other therapeutics strategy has developed in first-line therapy, as the FIRGEM phase II study that evaluated gemcitabine alone versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaanan, Aziz, Trouilloud, Isabelle, Markoutsaki, Theofano, Gauthier, Mélanie, Dupont-Gossart, Anne-Claire, Lecomte, Thierry, Aparicio, Thomas, Artru, Pascal, Thirot-Bidault, Anne, Joubert, Fanny, Fanica, Daniella, Taieb, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075567/
https://www.ncbi.nlm.nih.gov/pubmed/24929865
http://dx.doi.org/10.1186/1471-2407-14-441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075567/
https://www.ncbi.nlm.nih.gov/pubmed/24929865
http://dx.doi.org/10.1186/1471-2407-14-441

Ejemplares similares